JP2015531776A - ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 - Google Patents

３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 Download PDF

Info

Publication number
JP2015531776A
JP2015531776A JP2015530131A JP2015530131A JP2015531776A JP 2015531776 A JP2015531776 A JP 2015531776A JP 2015530131 A JP2015530131 A JP 2015530131A JP 2015530131 A JP2015530131 A JP 2015530131A JP 2015531776 A JP2015531776 A JP 2015531776A
Authority
JP
Japan
Prior art keywords
methyl
acid
compound
certain embodiments
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015530131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531776A5 (https=
Inventor
マン ホン‐ワ
マン ホン‐ワ
ダブリュー．レオング ウイリアム
ダブリュー．レオング ウイリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2015531776A publication Critical patent/JP2015531776A/ja
Publication of JP2015531776A5 publication Critical patent/JP2015531776A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2015530131A 2012-09-04 2013-09-03 ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 Pending JP2015531776A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261696727P 2012-09-04 2012-09-04
US61/696,727 2012-09-04
PCT/US2013/057786 WO2014039421A1 (en) 2012-09-04 2013-09-03 Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018061024A Division JP2018123142A (ja) 2012-09-04 2018-03-28 ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法

Publications (2)

Publication Number Publication Date
JP2015531776A true JP2015531776A (ja) 2015-11-05
JP2015531776A5 JP2015531776A5 (https=) 2016-10-27

Family

ID=49226507

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015530131A Pending JP2015531776A (ja) 2012-09-04 2013-09-03 ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法
JP2018061024A Withdrawn JP2018123142A (ja) 2012-09-04 2018-03-28 ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018061024A Withdrawn JP2018123142A (ja) 2012-09-04 2018-03-28 ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法

Country Status (6)

Country Link
US (2) US9682952B2 (https=)
EP (1) EP2892887B1 (https=)
JP (2) JP2015531776A (https=)
CN (1) CN104755472A (https=)
ES (1) ES2814952T3 (https=)
WO (1) WO2014039421A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501977A (ja) * 2016-01-14 2019-01-24 カンプ・バイオファーマスーティカルズ、リミテッドＫａｎｇｐｕ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｔｄ キナゾリン誘導体、そのための調製方法、医薬組成物、および適用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2892887B1 (en) 2012-09-04 2020-07-15 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
JP6359563B2 (ja) * 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
CA2941560A1 (en) * 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
SMT201700513T1 (it) 2013-05-01 2018-01-11 Celgene Corp Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione
WO2016109360A1 (en) * 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Dihydroquinazoline inhibitors of viral terminase
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
CN106518754B (zh) * 2016-09-28 2019-05-31 重庆中邦科技有限公司 一种制备2,3-二氯吡啶的方法
KR102368555B1 (ko) 2016-12-16 2022-02-28 강푸 바이오파마슈티칼즈 리미티드 조성물, 이의 적용 및 치료 방법
EP4467143B1 (en) 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
CN114401749B (zh) * 2020-06-29 2024-04-16 北京拓界生物医药科技有限公司 一种放射性核素标记物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512317A (ja) * 2003-11-24 2007-05-17 ファイザー・インク ピラゾロピリミジン類
JP2009515841A (ja) * 2005-11-15 2009-04-16 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト ビフェニル類の製造法
JP2009541284A (ja) * 2006-06-23 2009-11-26 アストラゼネカ・アクチエボラーグ プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用
JP2010504973A (ja) * 2006-09-26 2010-02-18 セルジーン・コーポレーション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
CA2545725A1 (en) 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
GB0506147D0 (en) 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
US20090298856A1 (en) 2005-05-11 2009-12-03 Rebecca Elizabeth Brown 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
CN101415689A (zh) 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有抗癌活性的经取代的喹唑啉
JP2009532450A (ja) 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ 化合物
CN101421253A (zh) 2006-04-18 2009-04-29 阿斯利康(瑞典)有限公司 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物
US9095596B2 (en) 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
PH12013501837A1 (en) 2011-03-11 2013-11-18 Celgene Corp Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
AU2012249491B2 (en) 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
AU2013202104B2 (en) 2012-01-13 2015-11-26 Celgene Corporation Biomarkers for the treatment of hepatocellular carcinoma
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP2892887B1 (en) 2012-09-04 2020-07-15 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
EP2892537A1 (en) 2012-09-10 2015-07-15 Celgene Corporation Methods for the treatment of locally advanced breast cancer
JP6359563B2 (ja) * 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
WO2014151180A1 (en) 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NZ629456A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
SMT201700513T1 (it) 2013-05-01 2018-01-11 Celgene Corp Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione
EP2991651A1 (en) 2013-05-03 2016-03-09 Celgene Corporation Methods for treating cancer using combination therapy
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TW201540323A (zh) 2014-01-15 2015-11-01 Celgene Corp ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
WO2015107196A1 (en) 2014-01-20 2015-07-23 Institut Curie Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
US20150258082A1 (en) 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
EP3827836A1 (en) 2014-06-27 2021-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
KR20170029565A (ko) 2014-07-11 2017-03-15 셀진 코포레이션 암 치료를 위한 병용요법
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
MX2017001620A (es) 2014-08-07 2017-05-10 Calithera Biosciences Inc Formas cristalinas de inhibidores de glutaminasa.
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
JP2017533727A (ja) 2014-10-13 2017-11-16 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2016153948A1 (en) 2015-03-20 2016-09-29 Deuterx, Llc Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
EP3277676B1 (en) 2015-03-25 2023-03-22 Pierre Fabre Médicament Substituted quinazoline derivatives as dna methyltransferase inhibitors
TW201642857A (zh) 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512317A (ja) * 2003-11-24 2007-05-17 ファイザー・インク ピラゾロピリミジン類
JP2009515841A (ja) * 2005-11-15 2009-04-16 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト ビフェニル類の製造法
JP2009541284A (ja) * 2006-06-23 2009-11-26 アストラゼネカ・アクチエボラーグ プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用
JP2010504973A (ja) * 2006-09-26 2010-02-18 セルジーン・コーポレーション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOSTER ALLAN B: "DEUTERIUM ISOTOPE EFFECTS IN THE METABOLISM OF DRUGS AND XENOBIOTICS: IMPLICATIONS FOR DRUG DESIGN", ADVANCES IN DRUG RESEARCH, vol. V14, JPN5015008764, 1 January 1985 (1985-01-01), GB, pages 1 - 40, ISSN: 0003687945 *
KUSHNER DJ: "PHARMACOLOGICAL USES AND PERSPECTIVES OF HEAVY WATER AND DEUTERATED COMPOUNDS", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. V77 N2, JPN5011007702, 1 February 1999 (1999-02-01), CA, pages 79 - 88, ISSN: 0003687946 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501977A (ja) * 2016-01-14 2019-01-24 カンプ・バイオファーマスーティカルズ、リミテッドＫａｎｇｐｕ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｔｄ キナゾリン誘導体、そのための調製方法、医薬組成物、および適用

Also Published As

Publication number Publication date
WO2014039421A1 (en) 2014-03-13
EP2892887A1 (en) 2015-07-15
US20150203469A1 (en) 2015-07-23
US9682952B2 (en) 2017-06-20
ES2814952T3 (es) 2021-03-29
CN104755472A (zh) 2015-07-01
US20180093965A1 (en) 2018-04-05
EP2892887B1 (en) 2020-07-15
JP2018123142A (ja) 2018-08-09

Similar Documents

Publication Publication Date Title
EP2892887B1 (en) Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
US9969712B2 (en) Process for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US11820720B2 (en) 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same
EP3524598B1 (en) A solid form of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
EP2699091B1 (en) 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US9642836B2 (en) Isotopologues of isoindole derivatives
JP2013543009A (ja) ３−ジュウテロ−ポマリドマイド
US8716314B2 (en) Isotopologues of thalidomide
EP3573979A1 (en) 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171128